09:05 EST PTC Therapeutics (PTCT) sees FY25 revenue $600M-$800M, consensus $963.31M
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics sees FY24 revenue ~$814M, consensus $795.38M
- PTC Therapeutics price target lowered to $58 from $63 at RBC Capital
- PTC Therapeutics submits NDA for vatiquinone in Friedreich ataxia
- PTC Therapeutics upgraded to Overweight from Equal Weight at Morgan Stanley
- Cantor Fitzgerald says ‘aggressively’ buy uniQure, PTC Therapeutics